[Karolinska Institutet] A prostate cancer research initiative in Sweden has been made possible by a donation from Björn Gysell. The investment will enable Karolinska Institutet’s research environment in prostate cancer to develop the next generation diagnostics and therapies using AI, genomics and precision medicine.

[Oncogene] Scientists identified SET domain bifurcated 1 (SETDB1) as a key regulator of epithelial–mesenchymal transition (EMT) and metastasis through direct repression of RhoB, the small GTPase. SETDB1 is genomically amplified and transcriptionally upregulated in metastatic CRPC.

[British Journal of Cancer] Researchers assessed poly (ADP‒ribose) polymerase (PARP) inhibitors alone and with androgen receptor pathway inhibitors in prostate cancer cell lines, metastatic patient-derived organoids, and LN-metastatic tissue slice cultures.

[NeoGenomics, Inc.] NeoGenomics, Inc. announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) companion diagnostic test approved by the US FDA for patients with prostate adenocarcinoma.

[Blue Earth Therapeutics (BioSpace)] Blue Earth Therapeutics and University College London announced initiation of a Phase I clinical trial evaluating Actinium (225Ac) rhPSMA-10.1 Injection, an investigational alpha‑emitting PSMA‑targeted radiopharmaceutical for the treatment of patients within clinical trials in metastatic CRPC.

[Cell Death & Disease] Investigators showed that the lactic acid-induced increase in succinate levels affects the activating H3K4me3 methylation mark in prostate cancer cells, promoting a pro-invasive phenotype.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers demonstrated continued dependency on ERG in metastatic prostate cancer and identified a druggable pocket within its N-terminal Pointed (PNT) domain.

[Advanced Healthcare Materials] Scientists utilized a cysteine-based, GSH-responsive polymer to deliver a broad-spectrum antitumor agent CBL0137. Exploiting high GSH levels in prostate cancer cells, the resulting CBL0137-loaded nanoparticles achieved targeted and efficient intracellular delivery and enhanced tumor-killing efficacy.

[Scientific Reports] The authors investigated whether the combined treatment of total flavonoids from Ageratum conyzoides and docetaxel (DTX) can enhance the antitumor effect of DTX on prostate cancer cells by regulating the NRF2/SLC7A11/GPX4 signaling axis and inducing mitochondria-related ferroptosis.

[Nature Reviews Urology] Novel immunotherapy approaches such as T cell-engager therapies, CD40 agonists and HSV-TK gene therapy have shown early promise for the treatment of prostate cancer.

[NPJ Biofilms and Microbiomes] Researchers profiled mammary single-cell transcriptomes in goats with ruminal dysbiosis-induced mastitis, complemented by ruminal metagenomic and untargeted metabolomic analyses of rumen fluid and serum.

[Karolinska Institutet] The Department of Oncology‑Pathology at Karolinska Institutet has announced the recipients of the 2026 Blue Sky Grant, an internal funding call aimed at supporting innovative, cross‑disciplinary research led by early‑career researchers.